Molecular Diagnostics VL

The Role of FoundationOne® Liquid CDx in mCRPC - Oliver Sartor

Details
Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss the US Federal Drug Administration (FDA) recent approval of the FoundationOne® Liquid CDx biopsy test that informs precision medicine in mCRPC. This is a companion diagnostic that serves as a predictive biomarker to identify patients who may benefit from targeted therapies including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibito...

Molecular Diagnostics and Genetic Testing in Genitourinary Cancers - Colin Pritchard and Heather Cheng

Details
Colin Pritchard, MD, PhD, Heather Cheng, MD, PhD, and Petros Grivas, MD, PhD, join Alicia Morgans, MD, MPH, to discuss the increasing role of molecular diagnostics and testing in genitourinary cancers. Dr. Pritchard begins by highlighting the advantages of the University of Washington and Seattle Cancer Care Alliance’s GU molecular tumor board. By providing clinicians the opportunity to discuss tu...

The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study - Mary-Ellen Taplin

Details
Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans to discuss the ProGen study. A randomized controlled trial that aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer. This...

The Ethics of Delivering Precision Medicine — Hala Borno

Details
Hala Borno joins Alicia Morgans and discusses a recent viewpoint article in JAMA Oncology titled “The Ethics of Delivering Precision Medicine—Pretest Counseling and Somatic Genomic Testing.” In the new era of precision medicine in cancer treatment, many clinicians use patient tumor genomic (somatic) data as part of routine clinical practice. Dr. Borno shares insights into Pretest Counseling in an...

Germline Testing for Patients with Genitourinary Malignancies - Maria Carlo

Details
Together with Alicia Morgans, Maria Carlo delves into the topic of germline testing for patients with genitourinary malignancies. In a more non-traditional approach to investigating the effects of DNA repair defects on prostate and bladder cancer, Carlo factors in not only oncological outcomes, but also psychological outcomes of her clinical trials. Biographies: Maria Carlo, MD, Medical Oncologist...

The Prevalence and Impact of Germline Mutations, PROREPAIR-B Trial - Elena Castro

Details
Elena Castro, MD joins Alicia Morgans, MD, MPH at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss PROREPAIR-B. This was an academic prospective observational study evaluating the prevalence and impact of germline mutations in BRCA1, BRCA2, ATM and PALB2 on metastatic castration-resistance prostate cancer (mCRPC) outcomes. Biographies: Elena Castro, MD, Prostate Cancer and Genitou...

Finding the Full Spectrum of Genetic Variants in Advanced Prostate Cancer - Rosalind Eeles

Details
In this conversation, Alicia Morgans and Rosalind Eeles discuss how patients should be selected for genetic counseling and testing. This discussion highlights several important questions including: What is the spectrum of genetic predisposition that we currently know? How should we use this? Who should be tested? Are there international discrepancies in the guidelines? How do we manage men who are...

Which Men Need Genetic Counseling and/or Testing? Presentation - Ros Eeles

Details
During the Molecular Biomarkers and Novel Imaging in Advanced Prostate Cancer session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019), Dr. Rosalind Eeles discussed how patients should be selected for genetic counseling and testing. She highlights several key points for clinicians to consider when thinking through how we should think about which men should be tested for genetic ab...

Count Me In! The Metastatic Prostate Cancer Project - Eliezer Van Allen

Details
Eli Van Allen shares details on The Metastatic Prostate Cancer Project, a project part of a larger nationwide genomic research project called "Count Me In" for men with advanced or metastatic prostate cancer. The Metastatic Prostate Cancer Project takes a new approach to cancer research in which researchers partner directly with men with metastatic and/or advanced prostate cancer, who share their...

Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective - Colin Pritchard

Details
In the era that genomics and genetics are really making an impact to clinical practice and with the recent positive results of the PROfound study, Alicia Morgans and Colin Pritchard have a discussion thinking about this data, how do we implement it, and how do we work with our pathologists to make things happen? Colin highlights this game-changing genomic markers data, particularly for homologous...